1RAWAT S, SUDHA V, RAKESH B, et al. Transdermal delivery by iontophoresis[ J ]. Indian J Pharm Sci, 2008, 70( 1 ): 5- 10.
2BATHEJA P, THAKUR R, MICHNIAK B. Transdennal iontophoresis[J]. Expert Opin Drug Deliv,2006, 3( 1 ) : 127 - 138.
3MAKOTO K, TOSHIO I, KOZO T, et al. Evaluation of skin barrier function using direct current Ⅱ: effects of duty cycle, waveform, frequency and mode [ J ]. Biol Pharm Bull, 2002, 25 (12) :1623 - 1628.
4ESTHER EB, ABRAHAM JD. Iontophoresis: a non-invasive ocular drug delivery[ J]. J Control Release,2006, 110 (3) : 479 - 489.
5SARA N, GUILIO F, MARINELLA Q, et al. In vitro transseleral iontophoresis of high molecular weight neutral eompounds [ J ].Eur J Pharm Sci,2009, 36(4 -5) : 486 -492.
6JETTE J. Buccal iontophoretic delivery of atenolol·HCl employing a new in vitro three-chamber permeation cell[ J]. J Control Release, 2001, 70(1 -2): 83-95.
7LIBERO IG, VIVIANA DC, GIULIA GG, et al. Diffusion of naltrexone across reconstituted human oral epithelium and histomorphological features [ J ]. Eur J Pharm Biopharm, 2007, 65 ( 2 ) : 238 - 246.
8BENOIT L, RICHARD HG, BEGONA DC. Reverse iontophoresis for non-invasive transdermal monitoring [ J]. Physiol Meas, 2004, 25(3): 35-50.
9VICTOR MM, MOLHMMAD AK, BOZENA BM. Enhanced iontophoretic delivery of buspirone hydrochloride across human skin using chemical enhancers[J], lnt J Pharm, 2003, 264( 1 -2) : 73 -83.
10VINCENT R, VERONIQUE P. Localization of a FITC-labeled phosphorothioate oligodeoxynucleotidc in the skin after topical delivery by iontophoresis and electroporation [ J ]. Pharm Res, 1995, 15(10) : 1596 - 1602.
